NasdaqGM - Nasdaq Real Time Price USD
Aerovate Therapeutics, Inc. (AVTE)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 5:04 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 996,671 | 8 |
| Sales | 58,938 | 7 |
| Net Shares Purchased (Sold) | 937,733 | 15 |
| Total Insider Shares Held | 5.2k | -- |
| % Net Shares Purchased (Sold) | -100.60% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| DAKE BENJAMIN T President | Conversion of Exercise of derivative security at price 1.74 per share. | Direct | 22,552 | Aug 1, 2024 |
| RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.67 per share. | Indirect | 1,549,944 | Jun 17, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 32,100 | Jun 14, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Conversion of Exercise of derivative security at price 14.59 per share. | Direct | 154,654 | Jun 14, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Sale at price 25.03 per share. | Direct | 375,450 | Jun 14, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Sale at price 25.00 per share. | Direct | 265,000 | Jun 14, 2024 |
| GILLIES HUNTER C Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 12,840 | Jun 13, 2024 |
| GILLIES HUNTER C Officer | Sale at price 24.50 per share. | Direct | 147,000 | Jun 13, 2024 |
| GILLIES HUNTER C Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 8,560 | May 17, 2024 |
| GILLIES HUNTER C Officer | Sale at price 21.07 - 21.86 per share. | Direct | 84,332 | May 17, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 21,400 | May 16, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Sale at price 21.52 - 21.92 per share. | Direct | 215,755 | May 16, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Sale at price 21.02 per share. | Direct | 41,631 | May 2, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 21,400 | May 1, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Sale at price 19.91 - 20.87 per share. | Direct | 230,946 | May 1, 2024 |
| GILLIES HUNTER C Officer | Conversion of Exercise of derivative security at price 1.74 per share. | Direct | 6,960 | Apr 17, 2024 |
| DAKE BENJAMIN T President | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 14,665 | Apr 17, 2024 |
| GILLIES HUNTER C Officer | Sale at price 22.30 - 23.33 per share. | Direct | 89,522 | Apr 17, 2024 |
| DAKE BENJAMIN T President | Sale at price 22.32 - 23.97 per share. | Direct | 153,327 | Apr 17, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 21,400 | Apr 16, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Sale at price 24.40 - 24.94 per share. | Direct | 246,971 | Apr 16, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 16,050 | Apr 10, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Sale at price 26.77 - 27.56 per share. | Direct | 201,392 | Apr 10, 2024 |
| GRAYZEL DAVID S Director | Sale at price 28.15 per share. | Indirect | 334,478 | Apr 9, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 21,400 | Apr 1, 2024 |
| DAKE BENJAMIN T President | Conversion of Exercise of derivative security at price 10.61 per share. | Direct | 35,278 | Apr 1, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 26,739 | Apr 1, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Conversion of Exercise of derivative security at price 14.59 per share. | Direct | 77,327 | Apr 1, 2024 |
| NOYES TIMOTHY P. Chief Executive Officer | Sale at price 28.96 - 31.95 per share. | Direct | 300,033 | Apr 1, 2024 |
| DAKE BENJAMIN T President | Sale at price 31.97 per share. | Direct | 106,317 | Apr 1, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Sale at price 31.23 per share. | Direct | 390,208 | Apr 1, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Sale at price 28.87 - 30.00 per share. | Direct | 154,697 | Apr 1, 2024 |
| GILLIES HUNTER C Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 19,260 | Mar 28, 2024 |
| GILLIES HUNTER C Officer | Sale at price 29.50 per share. | Direct | 265,500 | Mar 28, 2024 |
| DAKE BENJAMIN T President | Conversion of Exercise of derivative security at price 10.61 per share. | Direct | 117,431 | Mar 27, 2024 |
| DAKE BENJAMIN T President | Sale at price 27.97 per share. | Direct | 309,519 | Mar 27, 2024 |
| DAKE BENJAMIN T President | Conversion of Exercise of derivative security at price 10.61 per share. | Direct | 36,414 | Mar 25, 2024 |
| DAKE BENJAMIN T President | Sale at price 28.01 per share. | Direct | 96,119 | Mar 25, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Conversion of Exercise of derivative security at price 14.59 per share. | Direct | 77,327 | Mar 19, 2024 |
| VERWIJS MARINUS Chief Technology Officer | Sale at price 25.68 - 26.46 per share. | Direct | 138,243 | Mar 19, 2024 |
| GILLIES HUNTER C Officer | Conversion of Exercise of derivative security at price 1.74 - 2.14 per share. | Direct | 13,380 | Mar 18, 2024 |
| DAKE BENJAMIN T President | Conversion of Exercise of derivative security at price 2.14 - 10.61 per share. | Direct | 197,837 | Mar 18, 2024 |
| GILLIES HUNTER C Officer | Sale at price 25.81 - 26.40 per share. | Direct | 181,057 | Mar 18, 2024 |
| DAKE BENJAMIN T President | Sale at price 25.74 - 26.48 per share. | Direct | 908,046 | Mar 18, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 8,703 | Mar 13, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Sale at price 25.02 - 25.05 per share. | Direct | 101,815 | Mar 13, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 55,497 | Mar 11, 2024 |
| ELDRIDGE GEORGE ARTHUR Chief Financial Officer | Sale at price 25.00 - 26.30 per share. | Direct | 649,205 | Mar 11, 2024 |
| GILLIES HUNTER C Officer | Conversion of Exercise of derivative security at price 2.14 per share. | Direct | 19,206 | Mar 7, 2024 |
| GILLIES HUNTER C Officer | Sale at price 24.50 per share. | Direct | 219,888 | Mar 7, 2024 |
Related Tickers
IKNA Ikena Oncology, Inc.
1.7100
0.00%
SPRB Spruce Biosciences, Inc.
0.5190
+1.76%
ACRV Acrivon Therapeutics, Inc.
8.25
+4.83%
COGT Cogent Biosciences, Inc.
11.90
+2.23%
CGEM Cullinan Therapeutics, Inc.
16.77
-3.45%
BOLD Boundless Bio, Inc.
3.0500
+0.66%
SNSE Sensei Biotherapeutics, Inc.
0.4131
-5.25%
ACET Adicet Bio, Inc.
1.4500
-2.03%
TYRA Tyra Biosciences, Inc.
27.33
+5.20%
ARTV Artiva Biotherapeutics, Inc.
12.17
-4.77%